Ocugen to Acquire Innovimmune for up to $150M
Ticker: OCGN · Form: 8-K · Filed: Mar 21, 2024 · CIK: 1372299
| Field | Detail |
|---|---|
| Company | Ocugen, INC. (OCGN) |
| Form Type | 8-K |
| Filed Date | Mar 21, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, rare-disease, gene-therapy
TL;DR
Ocugen buying Innovimmune for $150M to boost rare disease pipeline. Deal expected Q2 2024.
AI Summary
Ocugen, Inc. announced on March 21, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests of Innovimmune Biotherapeutics, Inc. for an aggregate purchase price of up to $150 million. This acquisition is expected to strengthen Ocugen's rare disease pipeline, particularly with the addition of the gene therapy candidate OCU410. The transaction is anticipated to close in the second quarter of 2024.
Why It Matters
This acquisition significantly expands Ocugen's rare disease portfolio, potentially accelerating the development of new treatments for conditions like Leber congenital amaurosis and retinitis pigmentosa.
Risk Assessment
Risk Level: medium — The acquisition involves significant financial commitment and integration risks, and the success of the acquired gene therapy candidates is not guaranteed.
Key Numbers
- $150M — Acquisition Price (Maximum aggregate purchase price for Innovimmune Biotherapeutics, Inc.)
- Q2 2024 — Expected Closing (Anticipated timeframe for the acquisition to be completed.)
Key Players & Entities
- Ocugen, Inc. (company) — Acquiring company
- Innovimmune Biotherapeutics, Inc. (company) — Acquired company
- $150 million (dollar_amount) — Aggregate purchase price for acquisition
- OCU410 (drug_candidate) — Gene therapy candidate being acquired
- March 21, 2024 (date) — Date of definitive agreement
- second quarter of 2024 (date) — Expected closing period for the acquisition
FAQ
What is the primary strategic rationale behind Ocugen's acquisition of Innovimmune Biotherapeutics?
The acquisition is intended to strengthen Ocugen's rare disease pipeline, particularly with the addition of the gene therapy candidate OCU410.
What is the maximum potential purchase price for Innovimmune Biotherapeutics?
The aggregate purchase price is up to $150 million.
When is the acquisition expected to close?
The transaction is anticipated to close in the second quarter of 2024.
What specific gene therapy candidate is highlighted as a key asset from the acquisition?
The gene therapy candidate OCU410 is specifically mentioned as a key addition.
What type of diseases does Ocugen aim to address with the acquired assets?
Ocugen aims to address rare diseases with the acquired assets.
Filing Stats: 489 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-03-21 16:17:08
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share OCGN The Nasdaq
Filing Documents
- tm249483d1_8k.htm (8-K) — 22KB
- 0001104659-24-037301.txt ( ) — 189KB
- ocgn-20240321.xsd (EX-101.SCH) — 3KB
- ocgn-20240321_lab.xml (EX-101.LAB) — 33KB
- ocgn-20240321_pre.xml (EX-101.PRE) — 22KB
- tm249483d1_8k_htm.xml (XML) — 3KB
01 Regulation
Item 7.01 Regulation FD Disclosure On March 21, 2024, the United States Court of Appeals for the Third Circuit affirmed the U.S. District Court for the Eastern District of Pennsylvania's decision to dismiss with prejudice the consolidated securities class action lawsuits (Case No. 2:21-cv-02725 and Case No. 2:21-cv-03182) filed against Ocugen, Inc. The information in this Item 7.01 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this Current Report on Form 8-K. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 21, 2024 OCUGEN, INC. By: /s/ Shankar Musunuri Name: Shankar Musunuri Title: Chairman, Chief Executive Officer, & Co-Founder